Finn
NEOG Life sciences tools · Food safety · Animal health · Turnaround · Thesis updated August 11, 2026

A food safety turnaround finding early traction

01 Running thesis

Turnaround gaining momentum

Neogen is a turnaround story, and the new team is beginning to show results. The plan focuses on simplifying the company, cutting costs, fixing operations, and investing in higher-value food safety products. Recent quarters show strong execution, with Food Safety core growth accelerating to 5.8 percent, the highest level since 2023.

The best part of the story is the renewed focus on organic growth. Management is standing up a new innovation line for Petrifilm, aiming to release two new versions a year. This targets new markets beyond traditional food and beverage testing. At the same time, Animal Safety has rebounded as the team fixed major supplier disruptions.

The weak part is the near-term margin pressure. The company is increasing research and development investment by 50 percent for fiscal 2027 to fund its innovation and digital plans. That heavy spending limits how much profit margins can grow in the short run.

The bull case needs three things to happen together: close the Genomics sale, bring Petrifilm production in-house without disruption, and launch the planned new products successfully. The bear case is simple: the required investments push out margin targets, and the massive manufacturing transition leaves no room for error.

Jul 2026Q4 earnings showed core Food Safety growth accelerating and Animal Safety supply issues largely fixed. Management announced a large boost to research spending to drive Petrifilm innovation.
Apr 2026Management gave a clearer Petrifilm growth plan, including possible new uses in pharmaceuticals, cosmetics, and nutraceuticals. It also said the November 2026 manufacturing transition remains on schedule.
Apr 2026The Q3 filing showed a sharp Animal Safety hit from third-party supplier quality and manufacturing issues. Management expects some impact to continue into the start of fiscal 2027.
Jan 2026Q2 showed early turnaround progress, with positive core growth and a strong Petrifilm recovery. Management also pointed to about $20 million of annualized savings from cost cuts.
Oct 2025New CEO Mike Nassif laid out a more focused execution plan. The plan included cutting about 10 percent of positions and targeting about $20 million of annualized cost savings.
Oct 2025The Q1 filing confirmed the Cleaners and Disinfectants sale and debt reduction. It also kept pressure on the story because material weaknesses in internal controls remained unresolved.
Jul 2025The fiscal 2025 10-K showed a much higher risk profile, including a massive goodwill impairment and material weaknesses in internal controls. That made the turnaround case more dependent on operational repair.
Jul 2025Management signaled more portfolio simplification and interest in a Genomics sale. At the same time, tariff pressure and weak end markets kept the outlook cautious.
02 Business model

Tests, consumables, and channel trust

Neogen makes money by selling testing products, safety products, and related services. Many products are used over and over by food plants, labs, veterinarians, livestock producers, distributors, and animal health customers. That repeat use matters because the company is not only selling machines or one-time projects. Management is now shifting toward selling complete solutions rather than individual products.

Food Safety is the main engine. Customers use Neogen products to test for pathogens, allergens, toxins, sanitation problems, and other risks in food and feed. Rules around food testing and brand risk can support long-term demand, and core growth in this segment has been accelerating.

Animal Safety sells items such as rodent control, insect control, veterinary instruments, disposables, and biosecurity products. It also still includes Genomics until the Zoetis sale closes. This segment is more exposed to cyclical animal markets, supplier problems, and distributor behavior, though supply issues have recently stabilized.

The balance sheet is a key part of the story. Neogen carries significant debt from its acquisitions. Management plans to use Genomics sale proceeds to repay debt and strengthen its financial position while funding an ambitious research pipeline.

03 Product portfolio

What Neogen sells

Growth engine

Petrifilm and indicator testing

Petrifilm is a core Food Safety platform used for microbial testing. Management is building a new innovation line to deliver two new versions per year and expand into new consumer categories.

Steady

Pathogen detection

These products help food producers and labs detect harmful organisms. This line has helped drive recent Food Safety business growth.

Steady

Sample collection and culture media

These products support routine testing work in food plants and labs. They remain a core part of the daily testing workflow.

Steady

Natural toxins, allergens, and sanitation tests

These tests help customers check food, feed, and facilities for safety issues. Demand is tied to testing rules and customer quality programs.

Cash cow

Rodent, insect, and biosecurity products

These Animal Safety products help farms, facilities, and animal owners control pests and disease risks. The supply chain has stabilized after recent disruptions.

Steady

Veterinary instruments and disposables

Neogen sells tools and supplies used by vets and animal health customers. This product line faces cyclical demand in agricultural markets.

Option

Genomics services

Genomics provides testing services for production and companion animals. Neogen has agreed to sell this business to Zoetis, making it a near-term deleveraging asset.

04 Business segments

Food Safety drives the business

Food Safety74%modest
Animal Safety26%modest

Segment mix relies on trailing revenue data. Food Safety represents about three quarters of the business, but Genomics remains inside reported segments until the Zoetis deal closes.

05 Risk factors

What could break the plan

Petrifilm transfer disruption

High impact · Medium odds

Neogen is bringing Petrifilm manufacturing in-house, with the transition starting in November 2026. This is central to the Food Safety moat and margin story. If the transfer causes quality issues, backlogs, or lost customers, the bull case weakens fast.

We watchWatch the November 2026 transition date, duplicate manufacturing costs, customer qualification status, and Food Safety gross margin.

Investment pressures margins

Medium impact · High odds

Management is increasing research and development investment by 50 percent for fiscal 2027. The goal is to drive long-term organic growth, but this heavy spending will limit near-term profit margin expansion.

We watchWatch adjusted EBITDA margins, research spending levels, and the pace of new product launches.

Controls and reporting weakness

High impact · Medium odds

Neogen has disclosed material weaknesses in internal control over financial reporting. That means its systems and processes did not give enough assurance that financial reporting was reliable. The issue matters more during a complex turnaround with divestitures, restructuring, and integration work.

We watchWatch future 10-Q and 10-K control disclosures for a clean remediation statement.

Supply chain fragility

Medium impact · Medium odds

Earlier in 2026, Animal Safety suffered from severe third-party supplier quality and manufacturing problems. Management says they have resolved the majority of these issues, but supplier reliance remains an inherent risk.

We watchWatch Animal Safety revenue growth, product availability, recall updates, and management comments on suppliers.

Integration and transition overhang

Medium impact · Medium odds

The 3M Food Safety acquisition remains a source of operational risk. Prior integration challenges contributed to a large goodwill impairment in fiscal 2025. Moving smaller accounts to e-commerce channels could cause friction and near-term revenue leakage.

We watchWatch customer retention in smaller accounts, impairment commentary, and integration milestones.
06 Quick answers

In one breath

What does Neogen Corporation do?

Neogen sells food and animal safety products. Its Food Safety products help test food, feed, and facilities for contamination, while Animal Safety products serve vets, farms, livestock producers, and animal health channels.

Why is Neogen selling Genomics?

Management wants to simplify the company and focus on core Food Safety and Animal Safety products. Neogen agreed to sell Genomics to Zoetis and expects to use proceeds to reduce debt.

What is Petrifilm, and why does it matter?

Petrifilm is a key Food Safety testing platform that came with the 3M Food Safety business. Neogen wants to bring its manufacturing in-house and speed up innovation with two new versions per year.

What is the biggest near-term risk for Neogen stock?

The clearest near-term risk is execution. Investors need to see the Petrifilm manufacturing move stay on schedule without hurting customers, and margins must hold up during a heavy investment phase.

Get started with Finn today